Biotec Pharmacon may have the cure for diabetic foot ulcer with its pharmaceutical formulation of soluble beta glucan (SBG). What is already certain is that Biotec Pharmacon is moving quickly to market with formulations not only for diabetic foot ulcer, but for the treatment of oral mucositis after radio/chemotherapy and immunotherapy of cancer as well.
With Read more »
A look at this year’s biggest product launches, in terms of future sales potential, reveals that unsurprisingly biotechnology will be the source of 2009’s most valuable new drugs, with Amgen’s denosumab topping the table.
The following tables detail the ten biggest biotech and ten biggest conventional drugs that financial analysts expect to reach the market Read more »
Today’s decision by Novartis to license phase II anti-clotting agent elinogrel from private US biotech Portola Pharmaceuticals for USD 75 million upfront is both intriguing and surprising, considering that the current gold standard anti-thrombotic agent, Plavix, will be off-patent in two years and that the recent path to regulatory approval for Eli Lilly’s Effient was Read more »
Penwest Pharmaceuticals received a wake-up call when the phone began ringing off the hook following the release of the drug Opana® ER by a commercial partner. Yet to the company’s surprise people were not calling about the pain management compound the company had licensed. Instead it was the time release technology for oral drug delivery Read more »
With over 1,200 decision makers registered for the BIO-Europe Spring conference, and 1,500 expected to attend, industry executives are already lining up to take part in 16 conference panels and workshops. This year’s conference program includes business development sessions, therapeutic sessions, spotlight sessions and industry workshops, many of which will advise biotech companies on how Read more »
“V377 is the lead product coming out of PharmEste’s technology platform for the treatment of neuropathic pain that is expected to enter Phase I clinical trial in June, 2009” said Claudio Semeraro, former investor in biotechnology companies with Z-Cube, today the chief executive officer of PharmEste.
“Pharmeste is a biotech company bringing together know-how in TRPV1 Read more »
Although some bankers, consultants and lawyers are naturally delighted with Pfizer’s proposed USD 68 billion acquisition of Wyeth, an increasing consensus of opinion seems to be that the deal is no more than a stop-gap, designed to prop up the bottom line while failing to adequately address fundamental pipeline problems, which will ultimately only erode Read more »
Prior to coming to BIO-Europe Spring, Teva Pharmaceuticals, the world’s largest maker of generic drugs, said that it is seeking to deepen its range of branded products by buying rights to treatments for cancer and neurological and autoimmune disorders.
According to Bloomberg, Teva’s internal research pipeline will also continue to focus on “niche specialty disease Read more »
Newsletter